Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigation of the Underlying Mechanism of Zhibai Dihuang Pill in Treating Osteoporosis by using Network Pharmacology and Molecular Dynamics Simulation

Author(s): Yangyang Feng, Liangliang Zhang, Chengjin Zhao, Nannan Li and Baosheng Chang*

Volume 23, Issue 9, 2023

Published on: 03 March, 2023

Page: [1201 - 1214] Pages: 14

DOI: 10.2174/1871530323666221214144142

Price: $65

Abstract

Background: With society aging, the rising prevalence of osteoporosis (OP) has enormous social and economic implications. At present, the Zhibai Dihuang pill has been clinically applied in OP treatment and shown significant efficacy, but its underlying mechanism remains unclear.

Aims: This study was designed to explore the mechanism of the Zhibai Dihuang pill treating OP.

Methods: In this study, the active ingredients and corresponding targets in the Zhibai Dihuang pill were searched using the TCMSP platform. Based on the mRNA expression data of OP patients in the GEO database, differential expression analysis was conducted by bioinformatics means. By using the differentially expressed genes (DEGs), protein-protein interaction (PPI) network was constructed, and random walk with restart (RWR) analysis based on seed genes intersected from DEGs and drug target genes was conducted. On this basis, the drug-active ingredient-gene interaction network was built. The topological property of the network (degree) was statistically analyzed to find the key therapeutic target AKT1 for the treatment of OP. Molecular docking between AKT1 and the active ingredients was conducted, and according to the affinity score, diosgenin was determined as the key small molecule of the Zhibai Dihuang pill in OP treatment. Based on molecular dynamics simulation and cellular thermal shift assay validation, it was found that diosgenin had a good binding ability with AKT1.

Results: Cell experiments showed that diosgenin could affect the expression of bone markers and the mineralization of extracellular matrix in mouse osteoblasts by inhibiting the phosphorylation of AKT1, thus achieving the effect of OP treatment.

Conclusion: Based on network pharmacology, this study clarified the key small molecule compounds in the Zhibai Dihuang pill and their action targets and preliminarily analyzed the molecular mechanism of the Zhibai Dihuang pill treating OP, providing a theoretical basis for the clinical use of the Zhibai Dihuang pill.

« Previous Next »
Graphical Abstract

[1]
Aspray, T.J.; Hill, T.R. Osteoporosis and the ageing skeleton. Subcell. Biochem., 2019, 91, 453-476.
[http://dx.doi.org/10.1007/978-981-13-3681-2_16] [PMID: 30888662]
[2]
Burden, A.M.; Tanaka, Y.; Xu, L.; Ha, Y.C.; McCloskey, E.; Cummings, S.R.; Glüer, C.C. Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporos. Int., 2021, 32(5), 817-829.
[http://dx.doi.org/10.1007/s00198-020-05756-8] [PMID: 33305343]
[3]
Li, G.; Cheng, T.; Yu, X. The impact of trace elements on osteoarthritis. Front. Med. (Lausanne), 2021, 8, 771297.
[http://dx.doi.org/10.3389/fmed.2021.771297] [PMID: 35004740]
[4]
Zheng, B.; Ruan, G.; Ji, H. Research progress of TCM differentiation and treatment of osteoporosis. Jiangsu J. Trad. Chinese Med., 2018, 50, 78-81.
[http://dx.doi.org/10.3969/j.issn.1672-397X.2018.07.028]
[5]
Zhang, P. To investigate the underlying mechanism of Naringin in the treatment of osteoporosis on the basis of network pharmacology. Zhongguo Guzhi Shusong Zazhi, 2021, 27, 1006-7108.
[http://dx.doi.org/10.3969/j.issn.1006-7108.2021.04.013]
[6]
Wang, W. Effects of bushen chinese medicine on expression of cbfα1 in aging osteoblast of rat. Zhongguo Zhongyiyao Xinxi Zazhi, 2007, 14, 1005-5304.
[http://dx.doi.org/10.3969/j.issn.1005-5304.2007.11.014]
[7]
Wei, Y. Effects of Chinese medicine (Bushen) on expression of VDR protein in aging osteoblast. Zhongguo Guzhi Shusong Zazhi, 2006, 12, 1006-7108.
[http://dx.doi.org/10.3969/j.issn.1006-7108.2006.02.021]
[8]
Li, J.; Deng, C.; Liang, W.; Kang, F.; Bai, Y.; Ma, B.; Wu, C.; Dong, S. Mn-containing bioceramics inhibit osteoclastogenesis and promote osteoporotic bone regeneration via scavenging ROS. Bioact. Mater., 2021, 6(11), 3839-3850.
[http://dx.doi.org/10.1016/j.bioactmat.2021.03.039] [PMID: 33898880]
[9]
Luo, T.; Lu, Y.; Yan, S.; Xiao, X.; Rong, X.; Guo, J. Network pharmacology in research of chinese medicine formula: methodology, applica-tion and prospective. Chin. J. Integr. Med., 2020, 26(1), 72-80.
[http://dx.doi.org/10.1007/s11655-019-3064-0] [PMID: 30941682]
[10]
Lu, Z.; Huang, M.; Lin, H.; Wang, G.; Li, H. Network pharmacology and molecular docking approach to elucidate the mechanisms of Liuwei Dihuang pill in diabetic osteoporosis. J. Orthop. Surg. Res., 2022, 17(1), 314.
[http://dx.doi.org/10.1186/s13018-022-03194-2] [PMID: 35701780]
[11]
Zhu, R.; Du, B.; Yuan, J.; Yan, S.; Shao, M.; Sang, F.; Bi, Q.; Wang, Z.; Zhen, Q.; Fu, Y. Potential mechanisms of biejiajian pill in the treatment of diabetic atherosclerosis based on network pharmacology, molecular docking, and molecular dynamics simulation. Evid. Based Complement. Alternat. Med., 2022, 2022, 1-14.
[http://dx.doi.org/10.1155/2022/3296279] [PMID: 35990823]
[12]
Liu, H.; Wang, J.; Zhou, W.; Wang, Y.; Yang, L. Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice. J. Ethnopharmacol., 2013, 146(3), 773-793.
[http://dx.doi.org/10.1016/j.jep.2013.02.004] [PMID: 23415946]
[13]
Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 2015, 43(7), e47.
[http://dx.doi.org/10.1093/nar/gkv007] [PMID: 25605792]
[14]
Fang, H.; Gough, J. The ‘dnet’ approach promotes emerging research on cancer patient survival. Genome Med., 2014, 6(8), 64.
[http://dx.doi.org/10.1186/s13073-014-0064-8] [PMID: 25246945]
[15]
Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: a software envi-ronment for integrated models of biomolecular interaction networks. Genome Res., 2003, 13(11), 2498-2504.
[http://dx.doi.org/10.1101/gr.1239303] [PMID: 14597658]
[16]
Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5), 284-287.
[http://dx.doi.org/10.1089/omi.2011.0118] [PMID: 22455463]
[17]
Grant, B.J.; Skjærven, L.; Yao, X.Q. The BIO3D packages for structural bioinformatics. Protein Sci., 2021, 30(1), 20-30.
[http://dx.doi.org/10.1002/pro.3923] [PMID: 32734663]
[18]
Rodan, G.A.; Martin, T.J. Therapeutic approaches to bone diseases. Science, 2000, 289(5484), 1508-1514.
[http://dx.doi.org/10.1126/science.289.5484.1508] [PMID: 10968781]
[19]
Bouvard, B.; Annweiler, C.; Legrand, E. Osteoporosis in older adults. Joint Bone Spine, 2021, 88(3), 105135.
[http://dx.doi.org/10.1016/j.jbspin.2021.105135] [PMID: 33486108]
[20]
Li, H.; Yang, C.; Lan, M.; Liao, X.; Tang, Z. Arctigenin promotes bone formation involving PI3K/Akt/PPARγ signaling pathway. Chem. Biol. Drug Des., 2020, 95(4), 451-459.
[http://dx.doi.org/10.1111/cbdd.13659] [PMID: 31883507]
[21]
Zhao, S.; Niu, F.; Xu, C.Y.; Liu, Y.; Ye, L.; Bi, G.B.; Chen, L.; Tian, G.; Nie, T.H. Diosgenin prevents bone loss on retinoic acid-induced osteoporosis in rats. Ir. J. Med. Sci., 2016, 185(3), 581-587.
[http://dx.doi.org/10.1007/s11845-015-1309-2] [PMID: 26089290]
[22]
Zhang, Z.; Chen, Y.; Xiang, L.; Wang, Z.; Xiao, G.; Ju, D. Diosgenin protects against alveolar bone loss in ovariectomized rats via regulating long non coding RNAs. Exp. Ther. Med., 2018, 16(5), 3939-3950.
[http://dx.doi.org/10.3892/etm.2018.6681] [PMID: 30344672]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy